NEW YORK (GenomeWeb News) – Agilent Technologies company Dako today announced a companion diagnostic agreement with Pfizer.
The deal establishes a legal framework for the two firms to carry out R&D and commercialization work as well as advisory services, Dako said.
"This partnership with Dako will support Pfizer's companion diagnostics efforts, an important component of our growing precision medicine capabilities," John Hubbard, senior vice president of Development Operations at Pfizer, said in a statement. "Precision medicine R&D is designed to advance more targeted therapies for patients, improve efficacy, safety and success rates, and expedite development."
Financial and other terms of the alliance were not disclosed. Dako also did not provide specifics about drugs and disease areas of interest.
The deal is the second one covering the development of companion diagnostics forged by Dako since the start of the year, following a similar agreement with Eli Lilly announced last month. Agilent acquired Dako in June for $2.2 billion in a transaction that expands Agilent's footprint in the diagnostics space.
In addition to Pfizer and Eli Lilly, Dako has arrangements to develop companion diagnostics for Roche's Genentech and for Amgen.